On the stock market since 2025, it operates in the world of health and science. It has 27 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 27% a year on average.
Sales run at $20.3M a year. A small number, but proof the product has real buyers.
There is $3.0M in the vault; even if every debt were paid off, $631K would remain.
A loss of $27K against $20.3M in annual sales.
The stock sits at $0.41. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, HKPD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HKPD is a high-risk stock — not yet profitable, and its future rides on its product catching on.